EP1237874B1 - Selektive neurokinin-antagonisten - Google Patents

Selektive neurokinin-antagonisten Download PDF

Info

Publication number
EP1237874B1
EP1237874B1 EP00984340A EP00984340A EP1237874B1 EP 1237874 B1 EP1237874 B1 EP 1237874B1 EP 00984340 A EP00984340 A EP 00984340A EP 00984340 A EP00984340 A EP 00984340A EP 1237874 B1 EP1237874 B1 EP 1237874B1
Authority
EP
European Patent Office
Prior art keywords
mmol
compound
alkyl
solution
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00984340A
Other languages
English (en)
French (fr)
Other versions
EP1237874A2 (de
Inventor
Neng-Yang Shih
Ho-Jane Shue
Gregory A. Reichard
Sunil Paliwal
David J. Blythin
John J. Piwinski
Dong Xiao
Xiao Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP1237874A2 publication Critical patent/EP1237874A2/de
Application granted granted Critical
Publication of EP1237874B1 publication Critical patent/EP1237874B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/16—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/42—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/46—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Definitions

  • the present invention relates to a genus of substituted cyclic ureas and derivatives thereof useful as antagonists of tachykinin receptors, in particular as antagonists of the neuropeptides neurokinin-1 receptor (NK 1 ).
  • NK 1 neurokinin-1 receptor
  • Neurokinin receptors are found in the nervous system and the circulatory system and peripheral tissues of mammals, and therefore are involved in a variety of biological processes. Neurokinin receptor antagonists are consequently expected to be useful in the treatment or prevention of various mammalian disease states, for example respiratory diseases such as chronic lung disease, bronchitis, pneumonia, asthma, allergy, cough, bronchospasm; inflammatory diseases such as arthritis and psoriasis; skin disorders such as atopic dermatitis and contact dermatitis; ophthalmalogical disorders such as retinitis, ocular hypertension and cataracts; addictions such as alcohol dependence and psychoactive substance abuse; stress related disorders such as post tramautic stress disorder; obsessive/ compulsive disorders; eating disorders such as bulemia, anorexia nervosa and binge eating disorders; mania; premenstrual syndrome; central nervous system conditions such as anxiety, general anxiety disorder, panic disorder, phobias, bipolar disorders, migraine, epilepsy, nociception, emes
  • NK 1 receptors have been reported to be involved in microvascular leakage and mucus secretion, making NK 1 receptor antagonists especially useful in the treatment and prevention of asthma, emesis, nausea, depression, anxiety, cough, pain and migraine.
  • Ar 1 and Ar 2 are independently selected from the group consisting of R 17 .
  • heteroaryl and X 1 is -O-, -S-, -SO-, -SO 2 -. -NR 12 -, -N(COR 12 )- or -N(SO 2 R 15 )-;
  • Y' is H, C 1 -C 6 alkyl, -NR 17 R 13 , -SCH 3 , R 19 -aryl(CH 2 ) n6 -, R 19 -heteroaryl-(CH 2 ) n6 -, -(CH 2 ) n6 -heterocycloalkyl, -(C 1 -C 3 )alkyl-NH-C(O)O(C 1 -C 6 )alkyl or -NHC(O)R 15 ;
  • R 5 is H or -(CH 2 ) n1 -G, wherein n 1 is 0-5, G is H, -CF 3 , -CHF 2 , -CH 2 F, -OH, -O-(C 1 -C 6 alkyl), -SO 2 R 13 , -O-(C 3 -C 8 cycloalky
  • R 4 and R 7 are each H.
  • R 1 and R 3 are each H.
  • R 1 , R 3 , R 4 and R 7 are each H.
  • R 6 is preferably H or -OH.
  • X 1 is -O- or -NR 12 -.
  • Ar 1 and Ar 2 are each preferably R 8 , R 9 , R 10- phenyl, wherein R 8 , R 9 and R 10 are independently selected.
  • R 5 is H.
  • This invention also relates to the use of a compound of formula I in the treatment of, for example, respiratory diseases such as chronic lung disease, bronchitis, pneumonia, asthma, allergy, cough, bronchospasm; inflammatory diseases such as arthritis and psoriasis; skin disorders such as atopic dermatitis and contact dermatitis; ophthalmalogical disorders such as retinitis, ocular hypertension and cataracts; addictions such as alcohol dependence and psychoactive substance abuse; stress related disorders such as post tramautic stress disorder, obsessive/compulsive disorders; eating disorders such as bulemia, anorexia nervosa and binge eating disorders; mania; premenstrual syndrome; central nervous system conditions such as anxiety, general anxiety disorder, panic disorder, phobias, bipolar disorders, migraine, epilepsy, nociception, emesis, depression, psychosis, schizophrenia, Alzheimer's disease, AIDs related dementia and Towne's disease; gastrointestinal disorders such as Crohn's disease and colitis
  • the invention relates to a method for antagonizing the effect of Substance P at its receptor site or for the blockade of neurokinin-1 receptors in a mammal, comprising administering an amount of a compound of formula I effective to antagonize the effect of Substance P at its receptor site in a mammal in need of such treatment.
  • the invention in another aspect, relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I in a pharmaceutically acceptable carrier.
  • the invention also relates to the use of said pharmaceutical composition in the treatment of the mammalian disease states listed above.
  • the compounds of this invention can be combined with a selective serotonin reuptake inhibitor (SSRI) (i.e., the compounds of this invention can be combined with an SSRI in a pharmaceutical composition, or the compounds of this invention can be administered with an SSRI.
  • SSRI selective serotonin reuptake inhibitor
  • SSRIs include, without limitation; fluoxetine, fluvoxamine, paroxetine and sertaline, and pharmaceutically acceptable salts thereof.
  • Other compounds can readily be evaluated to determine their ability to selectively inhibit serotonin reuptake.
  • the invention in another aspect, relates to a method of treating the above diseases and disorders comprising administering an effective amount of an NK1 antagonist of formula I in combination with an SSRI described above.
  • the invention in another aspect, relates to a method of treating the above diseases and disorders comprising administering an effective amount of an NK1 antagonist of formula I in combination with an SSRI selected from: fluoxetine, fluvoxamine, paroxetine and sertaline, and pharmaceutically acceptable salts thereof.
  • an SSRI selected from: fluoxetine, fluvoxamine, paroxetine and sertaline, and pharmaceutically acceptable salts thereof.
  • the invention in another aspect, relates to a method of treating emesis, depression, anxiety, and cough comprising administering an effective amount of an NK1 antagonist of formula I in combination with an SSRI described above.
  • the compound of formula I and SSRI can be administered simultaneously, consecutively (one after the other within a relatively short period of time), or sequentially (first one and then the other over a period of time).
  • the antagonists are administered consecutively or sequentially, the NK1 antagonist of this invention (compound of formula I) is administered first.
  • R 8 is H or halogen
  • R 2 is H, -CH 3 or-CH 2 OH
  • R 6 is H or -OH
  • R 5 is selected from the group consisting of hydrogen and groups of the formula -(CH 2 ) n1 -G as follows, or -(CH 2 ) n1 -G', wherein n 1 is 2-4 and G' is H, -OH, -OCH 3 -, -OEt, -O(i-Pr), -O-cyclopropyl, or -CONR 13 R 14 , wherein R 13 and R 14 are independently selected from the group consisting of H, -CH 3 , Et, i-Pr, or cyclopropyl (Et is ethyl and i-Pr is isopropyl).
  • X 1 is -O-, -NH-, -N(CH 3 )- or -N(COCH 3 )-;
  • R 8 is H or halogen;
  • R 2 is H, -CH 3 or -CH 2 OH;
  • R 9 is -OCF 3 or 5-(trifluoromethyl)-1 H-tetrazol-1-yl;
  • R 6 is H or -OH;
  • R 12 is -CH 3 or cyclopropyl;
  • R 5 is selected from the group consisting of hydrogen and groups of the formula -(CH 2 ) n1 -G as shown above for structures Ia and Ib.
  • Preferred compounds of the invention are the compounds of examples 2, 61, 79a, 79b, 92, 93, 126, 127, 128, 129, 165a, 165b, 166a and 166b.
  • alkyl means straight or branched alkyl chains.
  • Lower alkyl refers to alkyl chains of 1-6 carbon atoms and, similarly, lower alkoxy refers to alkoxy chains of 1-6 carbon atoms.
  • Cycloalkyl means cyclic alkyl groups having 3 to 8 carbon atoms.
  • Aryl means phenyl, naphthyl, indenyl, tetrahydronaphthyl, indanyl, anthracenyl or fluorenyl.
  • R 16 -aryl and R 19 -aryl refer to such groups wherein substitutable ring carbon atoms have an R 16 or an R 19 substituent.
  • Halogen refers to fluoro, chloro, bromo or iodo atoms.
  • heteroaryl groups furanyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridyl, pyrimidyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl and triazinyl.
  • benzofused heteroaryl groups are benzimidazolyl, benzofuranyl, benzo-thiophenyl, benzoxazolyl, indolyl and quinolyl. N-oxides of nitrogen-containing heteroaryl groups are also included.
  • R 19 -heteroaryl refer to such groups wherein substitutable ring carbon atoms have an R 19 substituent.
  • R 8 , R 9 or R'° is heteroaryl, it is preferably tetrazolyl substituted by H, C 1 -C 4 alkyl, C 3 -C 8 cycloalkyl, -CF 3 -SO 2 -(C 1 -C 6 alkyl) or -OCF 3 .
  • Heterocycloalkyl refers to a 4- to 7-membered saturated ring comprising 1 to 3 heteroatoms independently selected from the group consisting of -O-, -S- and - NR 21 -, wherein R 21 is H or C 1 -C 6 alkyl, and wherein the remaining ring members are carbon. Where a heterocyclic ring comprises more than one heteroatom, no rings are formed where there are adjacent oxygen atoms, adjacent sulfur atoms, or three consecutive heteroatoms. Examples of heterocyclic rings are tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, morpholinyl, thiomorpholinyl and piperazinyl.
  • variables R 1 to R 26 are said to be independently selected from a group of substituents, we mean that R 1 , R 2 , R 3 , etc., are independently selected, but also that where an R 8 , for example, occurs more than once in a molecule, those occurrences are independently selected (e.g., if X 1 is -NR 12 - wherein R 12 is hydrogen, G can be -COOR 12 wherein R 12 is methyl).
  • R 8 , R 9 and R 10 can be independently selected from a group of substituents, and where more than one R 8 , R 9 or R 10 is other than hydrogen, the substituents are independently selected; those skilled in the art will recognize that the size and nature of the substituent(s) will affect the number of substituents which can be present.
  • the "Q" groups are always joined to the rest of the molecule as shown, i.e., they are attached left-to-right, where -X 2 - or -NR 5 - is attached to the carbon to which R 6 and R 7 are attached, and -NR 4 - is always attached to the carbon to which Ar 1 is attached.
  • Compounds of formula I can have at least one asymmetrical carbon atom and all isomers, including diastereomers, enantiomers and rotational isomers are contemplated as being part of this invention.
  • the invention includes d and I isomers in both pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting materials or by separating isomers of a compound of formula I.
  • Compounds of the invention which have an amino group can form pharmaceutically acceptable salts with organic and inorganic acids.
  • suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, tartaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art.
  • the salt is prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt.
  • the free base form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium bicarbonate.
  • the free base form differs from its respective salt form somewhat in certain physical properties, such as solubility in polar solvents, but the salt is otherwise equivalent to its respective free base forms for purposes of the invention.
  • Certain compounds of the invention which are acidic form pharmaceutically acceptable salts with inorganic and organic bases.
  • examples of such salts are the sodium, potassium, calcium, aluminum, gold and silver salts.
  • salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.
  • R 1 , R 2 and R 3 are each H but, depending on the leaving group L, it may work effectively if either R 1 , R 2 or R 3 is C1-C6 alkyl.
  • a leaving group, L, of choice is CF 3 SO 2 - (triflate) but others also suffice, such as Br or I.
  • the base used may vary but is preferably one of the hindered non-nucleophilic kind, of which an example is 2,6-di-tert-butyl-4-methyl pyridine.
  • the alkylating agent (3a) in which L is triflate may be prepared from the alcohol-type starting material (4) using triflic anhydride and the same hindered, non-nucleophilic base as is used for the alkylation.
  • a metallic cyanide e. g. KCN
  • NH 4 ) 2 CO 3 results in the formation of the hydantoin, a process well known to those skilled in the art of organic synthesis:
  • Selective reduction of the amide carbonyl and not the urea carbonyl may be accomplished by using a mixture of lithium aluminum hydride (LAH) and AlCl 3 as a preferred method although other methods are also available, such as the use of LAH in ether or THF at or above room temperature, up to the boiling point of the solution.
  • LAH lithium aluminum hydride
  • R 4 and R 5 are both H.
  • substitution reaction at the nitrogen atoms of (5) may be accomplished using one of many sets of conditions used for such transformations, for example, use of an organic base, such as triethylamine or Hunig's Base (di-isopropyl ethylamine) and the appropriate alkylating agent, L-R 5 .
  • the ketone (2) may also be made by the following sequence of reactions.
  • the alcohol (1) may be converted to its alkoxide anion using a strong base, such as lithium bis(trimethyl silyl)amide or the like, followed by reaction, in an inert solvent, such as THF, with the N,O-dimethyl amide of the iodo-acid (7) to produce (8) which is known as a "Weinreb amide".
  • organometallic reagents include the Grignard (M is Mg) or lithium reagent.
  • Suitable media for this reaction include neutral, non-reactive solvents such as ether or THF.
  • the ketone (2) may next be reacted with trimethylsilylcyanide in the presence of a Lewis acid catalyst, such as Znl 2 , and subsequently treated with saturated NH 3- CH 3 OH at ambient temperature to yield an intermediate which may be reduced directly to diamine (10) using a powerful hydride reducing agent such as LAH in a neutral solvent such as THF.
  • a Lewis acid catalyst such as Znl 2
  • Reaction of the diamine (10) with a reagent known to introduce a carbonyl between two amines located in the correct position leads to the cyclic ureas (5) which are compounds of the invention.
  • reagents are COCl 2 , carbonyl diimidazole and methyl or ethyl chloroformate.
  • Subsequent modification by introduction of R 4 and R 5 groups may be performed as described in Method 1.
  • reaction described above can also be used to prepare compounds of the invention in which X 1 is -S- by employing the thiol corresponding to the alcohol (4) shown above.
  • a further use of compounds such as 10A is to introduce the guanidine functions into compounds of the invention.
  • Reacting (10A) with CH 3 l in a neutral solvent, such as CH 3 CN, THF, or a mixture of the two produces the S-methyl derivative (10B) which may then be reacted with an amine, R 11 -NH 2 , to produce guanidines (10C) or a tautomer.
  • the diamine (10) is also a useful intermediate for preparation of products of the invention in which X 2 is -NR 5 -.
  • the group R 5 is introduced by use of an aldehyde or ketone precursor of R 5 by a process of reductive amination (otherwise known as reductive alkylation of the amine (10)).
  • a proviso of this method is that the R 5 group may not contain a quaternary carbon atom next to the nitrogen atom. It also cannot be H, nor certain other of the definitions of R 5 , for example, when G is -OH, -SO 2 R 13 or -NR 13 R 14 etc., then n 1 cannot be 0.
  • the starting material (10D) will be used. By reacting.
  • a variable amount of the isomeric structure (10F) may also form in this reaction, depending upon the reactants. It may be separated from (10E) by conventional chromatographic methods and reacted, as above, to yield compounds of the invention in which R 4 is the introduced substituent instead of R 5 .
  • a further use for the diamine (10) is in the preparation of compounds of the invention in which Y' is as defined above, except that it is not -NH 2 , -NHCH 3 or - SCH 3 .
  • the diamine (10) may be heated with a carboxylic acid, Y 1 -CO 2 H, in a high boiling, neutral solvent, such as toluene to produce the amidines (10G) of the invention:
  • An alcohol (3) may be reacted with an O-substituted hydroxylamine derivative, preferably methoxylamine to yield the oxime derivative (11).
  • Conversion of the oxime to the alkoxide may be performed using a strong base, such as NaH, in a non-hydroxylic solvent, such as THF.
  • a diprotected aryl glycine ester such as (14), in which "Prot” is a protecting group, preferably benzyl, and “E” is an ester group, preferably methyl or ethyl, may be converted to its anion using a strong base, such as lithium diisopropylamide, in an ether solvent, such as THF, at a temperature of about -78 °C.
  • Reaction of the anion with a halo-nitrile in which "Hal” is preferably I, at temperatures between -78 °C and 0°C results in the protected intermediate (16).
  • the alcohol (19) may be converted to a compound of the invention (20), by reaction of the mono-anion prepared by using a strong base, such as NaH, with a benzyl halide in the presence of Ag 2 O.
  • a strong base such as NaH
  • a benzyl halide in the presence of Ag 2 O.
  • “Hal” is as defined above and the solvent is preferably a polar, non-hydroxylic solvent such as DMF.
  • the intermediate (17), above, may also be converted to compounds of the invention via its di-BOC protected derivative (21).
  • Such intermediates may be converted to the ethers (22) by reaction with an aryl halide (23), preferably a bromide or iodide.
  • an aryl halide preferably a bromide or iodide.
  • Use of silver oxide (Ag 2 O) as a catalyst and base is desirable.
  • BOC protecting groups under standard conditions (e.g. HCl/ether) produces the diamine which may be cyclized to compounds of the invention using the same reagents as described earlier in Method 2, e.g. COCl 2 , carbonyl diimidazole, sulfonyl diimidazole, etc.
  • Reactive groups not involved in the above processes can be protected during the reactions with conventional protecting groups which can be removed by standard procedures after the reaction.
  • Table 1 shows some typical protecting groups:
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • the powders and tablets may be comprised of from about 5 to about 95 percent active ingredient.
  • Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
  • a pharmaceutically acceptable carrier such as an inert compressed gas, e.g. nitrogen.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
  • liquid forms include solutions, suspensions and emulsions.
  • the compounds of the invention may also be deliverable transdermally.
  • the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the compound is administered orally.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the quantity of active compound in a unit dose of preparation for treatment of respiratory diseases; inflammatory diseases; skin disorders; ophthalmalogical disorders; addictions; stress related disorders; obsessive/compulsive disorders; eating disorders; mania; premenstrual syndrome; central nervous system conditions; gastrointestinal disorders; bladder disorders; atherosclerosis; fibrosing disorders; obesity; Type II diabetes; pain related disorders; and genitourinary disorders; may be varied or adjusted from about 1 mg to about 1500 mg, preferably from about 50 mg to about 500 mg, more preferably from about 20 mg to about 200 mg, according to the particular application.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • a typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 1500 mg/day, in two to four divided doses.
  • RT room temperature
  • Me is methyl
  • Bu is butyl
  • Br is bromo
  • Ac is acetyl
  • Et is ethyl
  • Ph phenyl
  • THF is tetrahydrofuran
  • EtOAc is ethyl acetate
  • Et 2 O is ether
  • LAH is lithium aluminum hydride
  • CDI is 1,1-carbonyl diimidazole
  • HOBT hydroxybenzotriazole
  • DEC 1,2-diethylaminoethyl chloride
  • TFA is trifluoroacetic acid
  • Et 3 N is triethylamine
  • MTBE is t -butyl methyl ether
  • DAST is diethylaminosulfur trifluoride.
  • Step 1
  • Trimethyl silyl cyanide (0.92 ml, 6.9 mmol) was added to a flask containing a solution of 4 (2.0 g, 5.52 mmol) in CH 2 Cl 2 (11 ml), cooled with a water bath, followed by addition of Znl 2 (88 mg, 0.276 mmol). The reaction was finished in 1 h. The insoluble Znl 2 was filtered off and rinsed with CH 2 Cl 2 . Evaporation of the solvent yielded a light yellow oil as crude product which was used in the next step.
  • the crude material 5 was treated with saturated NH 3 -CH 3 OH (10 ml) and heated in an oil bath under N 2 at 45 °C. After 2 h of heating, solid was filtered off and the filtrate was concentrated to give 5a .
  • Step 1
  • the racemic compound was separated with a Chiralcel OD column, eluting with CH 3 CN to give enantiomers A and B.
  • the enantiomers A and B were reduced separately with LAH-AlCl 3 to give chiral compounds A and B. Pure chiral B was obtained by crystallization from hot CH 3 CN and hexane.
  • Compound 19 was prepared by an analogous method to that of Example 1 (step 4) using compound 18 in place of compound 4 .
  • the title compound was prepared by a method analogous to that described for Example 1 (step 5) using compound 19 in place of compound 6 .
  • Two sets of diastereomers A and B were isolated by flash silica chromatography at compound 19 stage and these were cyclized separately to the title compounds with CDI reagent.
  • the title compound was prepared by an analogous method to that described for Examples 1 and 3 using ⁇ -methyl-3,5 -bis(trifluoromethyl)-benzyl alcohol in place of 3,5-bis(trifluoromethyl)benzyl alcohol. Two sets of diastereomers were isolated by flash silica chromatography at compound 21 stage and cyclized separately to the title compound with CDI reagent. Diastereomer A of the title compound, FAB MS [M+1] + 433.1358, calculated [M+1] + 433.1351; diastereomer B of the title compound, FAB MS [M+1] + 433.1358, calculated [M+1] + 433.1351.
  • the filtrate was further purified by flash grade silica gel, eluting with 6% NH 4 OH-CH 3 OH (1:9) / 94 % CH 2 Cl 2 to give compound 28 (1.3 g) as a solid with a total yield of 64 %.
  • Step 4
  • the compound was treated with one equivalent of 1 N HCl - Et 2 O solution and isolated as the HCl salt.
  • ketone intermediate 66 was prepared by analogous methods as described for Examples 1 and 2, except for the preparation of ketone intermediate 66 .
  • Compound 66 was prepared by treatment of compound 64 (24.1 g, 98.8 mmol) and 2, 6-di-t-butyl-4-methyl pyridine (42 g, 206 mmol) in dry CH 2 Cl 2 (400 ml) at 0 °C with slow addition of trifluoromethyl-methane sulfonic anhydride (30 g, 107 mmol) under a N 2 atmosphere. After stirring at RT for 1 h, a solution of compound 64 (14 g, 82.3 mmol) in CH 2 Cl 2 (200 ml) was added dropwise.
  • the title compound was prepared by a method analogous to that described in Example 25 for compound 61 in step 1, using compound 7 in place of compound 13 and N, N-dimethyaminoethyl chloride hydrochloride in place of 1-(2-chloro-ethyl)-morpholine hydrochloride.
  • the title compound was obtained as a solid in a 96 % yield. Electrospray MS [M+1] + 504.1.
  • the title compound was prepared by a method analogous to Example 10, using 6 in place of 22.
  • the title compound was obtained as a HCl salt, FAB MS [M+1] 502.1.
  • Example 62 To a solution of Example 62 (180 mg, 0.41 mmol) in dioxane (4 ml), sulfamide (48.5 mg, 0.51 mmol) was added. After heating to 110°C for 5 h, the reaction was concentrated. The residue was purified by flash chromatography, eluting with 4% NH 4 OH:CH 3 OH(1:9) in CH 2 Cl 2 . The title compound was collected as off-white solid (35 mg, 17%). FAB MS [M+1] + 518.1.
  • Pure 80 was obtained as a solid (1.41 g, 3.25 mmol) in 82% yield by flash silica chromatography (50 g), eluting with 5 % (1:9) [NH 4 OH/CH 3 OH] /95 % CH 2 Cl 2 .
  • 89 was prepared by a method analogous to Examples 61 and 62, using s-(+)-2-phenylglycine methyl ester hydrochloride in place of (s)-N-BOC-4-fluorophenyl-glycine in Example 61.
  • a mixture of 89 (2.03 g, 5 mmol) in THF (6 ml) and 1,1'-thiocarbonyldiimidazole(1.34 g, 7.5 mmol) was stirred under N 2 at RT for 18 h.
  • Example 76 The title compound was prepared by a method analogous to Example 76 using Example 62 in place of Example 71. Purification the crude material by flash silica chromatography, using 5% (1:9)[NH 4 OH/CH 3 OH]/95 % CH 2 Cl 2 gave the title compound as a solid with a yield of 75%. LCMS [M+1] + 463.1.
  • a flame-dried flask was charged with 98 (5.10 g, 20.1 mmol, 1.0 eq) and anhydrous toluene (56 ml). This cloudy solution was heated up to 140-150 °C. 36 ml of dry toluene was azeotropically distilled through a Dean-Stark trap with an air condenser. Another 36 ml of toluene was added. This azeotropical distillation was repeated three times to ensure 98 was totally dry. After the third azotropical distillation was done, another 36 ml of anhydrous toluene was added. The solution was allowed to cool down toRT.
  • Amino amide 104 (14.14 g, 32.55 mmol, 1 equiv.) (prepared in a similar procedure to that described in Example 92, substituting 103 in place of 92 in step 4) was taken up in dry CH 2 Cl 2 (120 ml). The solution was cooled to -78°C and chlorosulfonyl isocyanate (2.84 ml, 32.55 mmol, 1 equiv.) was added. The reaction was stirred at 0°C for 3 h and then concentrated to a white solid.
  • the title compound was prepared by a method analogous to Example 92 using 111 in place of 92 for step 4.
  • Example 92 The product of Example 92 (0.25g, 0.59 mmol, 1.0 equiv.) was taken up in 4 ml dry DMF and cooled to 0 °C in a ice bath. NaH (60% dispersion in mineral oil) (0.0179g, 0.59 mmol, 1.0 equiv.) was added to the reaction mixture, the solution was warmed to RT and stirred for 45 min. CH 3 l (0.053 ml, 0.66 mmol, 1.1 equiv.) was added and reaction mixture was stirred at RT over night. The reaction was monitored by TLC in 4/1 EtOAc/Hexane. The reaction did not go to completion, hence was quenched with H 2 O (3x15ml).
  • Example 96 The following examples were prepared in a similar fashion to Example 96, using 116 to prepare Example 116 and Example 115 to prepare Example 117 in place of hydroxyureas from Examples 94 and 95:
  • Example 103 To a solution of Example 103 (170 mg, 0.306 mmol) in CH 2 Cl 2 was added solid Oxone (1.14g, 17.4 mmol), the resulting suspension was stirred vigorously for 20 h, then quenched with saturated NaHCO 3 solution and extracted with EtOAc. The organic layers were washed with brine, dried over Na 2 SO 4 and concentrated. Flash chromatography afforded the title compound. Electrospray MS [M+1] + 57 1.1
  • Example 120 To a solution of Example 120 in CH 2 Cl 2 was added m-CPBA and the resulting solution was stirred for 30 h, then quenched with NaHCO 3 solution and extracted with EtOAc. The organic layers were washed with brine, dried over Na 2 SO 4 and concentrated. Flash chromatography afforded the title compound. Electrospray MS [M+1] + 587.1.
  • Example 92 To Example 92 (0.150 g, 0.36 mmol), CsF (0.109 g, 0.72 mmol) in DMF (3.5 ml) at 0°C and NaH 0.018 g (60% in mineral oil) was added. After stirring for 10 min, 2,5-difluorobenzonitrile (0.0587 g, 0.0378 mmol) was added in small portions. The solution was allowed to warm to 23 °C and was stirred overnight. The reaction was quenched with saturated NH 4 Cl solution, extracted with EtOAc, and the combined organic layer was washed with water and brine, dried over Na 2 SO 4 and concentrated. Flash chromatography afforded the title compound (0.051 g, 26%). Electrospray MS [M+1] + 538.1.
  • step 1 The product of step 1 was converted to Examples 128 and 129 using procedures similar to Examples 126 and 127, steps 2-3, using LAH in place of LAH/AlCl 3 in step 2 to provide 0.14 g of the products, obtained as mixture of two isomers.
  • HPLC separation on chiralpak AD column using (85/15) hexane/IPA mixture gave 80 mg (29% yield) of Example 129, FAB, (M +1 ) 449.2 and 30 mg (11% yield) of Example 128 FAB, (M +1 ) 449.2.
  • Example 93 0.1 g, 0.23 mmol, 1.0 equiv.
  • POCl 3 0.024 ml, 0.254 mmol, 1.1 equiv.
  • the mixture was warmed to RT, stirred for 30 min, and poured into 5 g ice.
  • the resultant mixture was poured into water (100 ml) and extracted with EtOAc (100 ml).
  • the organic layer was separated, washed with saturated aq. NaCl (1 x 100 ml), dried over anhydrous Na 2 SO 4 and concentrated. Flash chromatography over 200 ml silica using (1) 4/1 hex/EtOAc, and (2) 1/1 hex/EtOAc gave 0.070 g (66% yield) of 118 as solid.
  • Example 136 was used as the starting cyclic urea.
  • Example R 5 R 4 R 8 MS [M+1] + 135 Me H H 447.1. 136 Et H H 461.1. 137 H Et H 461.1. 138 i Pr H H 475.1. 139 Et H F 479.1.
  • Example 140 The title compounds were prepared using procedures similar to those in Example 94, using ethyl isocyanate in place of methyl isocyanate. Purification via HPLC (Chiralpak AD column using 98/2 hex/isopropanol) provided Example 140 MS [M+1] + 477.1 and Example 141 MS [M+1] + 477.1.
  • Example 92 To Example 92 (2.0 g, 4.78 mmol) in THF (15 ml) at 0°C was added NaNO 2 (0.39 g, 5.7 mmol) in H 2 O (7.5 ml), then H 2 SO 4 (conc.) (1 ml) was added slowly. The solution was allowed to warm to 23°C and stirred for 1 h. It was then diluted with water and extracted with EtOAc. The organic layers were washed with NaHCO 3 solution, brine, dried over Na 2 SO 4 and concentrated to give the title compound. Electrospray MS [M+1] + 448.1.
  • Example 143 (0.95 g, 2.1 mmol) in Et 2 O (10 ml) at 0° C was added dropwise LiAlH 4 (4.2 ml, 1 M in Et 2 O). The solution was allowed to warm to 23°C and stirred for 2 hr. It was quenched with saturated K,Na tartrate solution and then partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na 2 SO 4 and concentrated to give the title compound. Electrospray MS [M+1] + 434.1
  • Example 144 To Example 144 (0.3 g, 0.69 mmol) in acetic acid (3 ml) was added 2,5-dimethoxy-3-tetrohydrofuran (3 ml) and the mixture was heated at 70° C for 1.5 h. It was cooled to 23°C and diluted with EtOAc. The organic layers were washed with NaHCO 3 , brine, dried over Na 2 SO 4 and concentrated. A stream of N 2 was introduced into the residue to remove excess 2,5-dimethoxy-3-tetra-hydrofuran. The crude product was purified by silica gel chromatography to give the title compound. Electrospray MS [M+1] + 484.1.
  • Example 144 (0.65 g, 1.5 mmol) in pyridine (15 ml) was concentrated under reduced pressure at 50° C using a water bath. The procedure was repeated twice. The residue was treated with 1,2-diformylhydrozine (0.34g, 3.6 mmol), followed by the addition of pyridine (7.5 ml), Et 3 N (1.5 ml) and TMSCI (3 ml). The thick paste was heated at 80 °C under N 2 for 65 h, then concentrated under reduced pressure to give a yellow residue. The residue was partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na 2 SO 4 and concentrated to give a crude product. Further purification using biotage followed by a prep TLC afforded the title compound. Electrospray MS [M+1] + 486.1.
  • Example 147 To a cooled solution of Example 147 (0.3 g, 0.70 mmol), DEC (0.14 g, 0.73 mmol), HOBT (0.1 g, 0.74 mmol) and NaSO 4 (0.59 g) in anhydrous CH 2 Cl 2 (4.5 ml), glacial acetic acid (0.05 ml, 0.87 mmol) was added followed by Et 3 N (0.1 ml, 0.72 mmol). The reaction was allowed to react for 18 h at RT, then quenched with brine. The aqueous solution was extracted with CH 2 Cl 2 (50 ml X 3). The combined organic layer was dried, filtered and concentrated. The pure title compound was obtained through flash chromatography, eluting with 2% (1:9) NH 4 OH-CH 3 OH in CH 2 Cl 2 to give the final product in 39% yield. Electrospray MS [M+1] + 474.1.
  • Example 147 To a cooled solution of Example 147 (0.2 g, 0.46 mmol) in anhydrous CH 2 Cl 2 (5 ml) at 0 °C, trifluoroacetic anhydride (0.09 ml, 0.64 mmol) neat was added followed by Et 3 N (0.08 ml, 0.57 mmol). The reaction was allowed to react for 18 h at RT. Volatile solvents were evaporated. The pure title compound was obtained through flash chromatography, eluting with 50% EtOAc in hexane to give the final product in 33% yield. Electrospray MS [M+1] + 528.1.
  • Example 82 A solution of Example 82 (0.2 g, 0.464 mmol) in CH 2 Cl 2 (2 ml) and isocyanate (53 mg, 0.93 mmol was stirred under N 2 at RT for 18 h. After work-up, a solid was obtained as a crude product which was then purified by chromatography, eluting with 2 % NH 3 -CH 3 OH (1:9) / 98 % CH 2 Cl 2 to give the title compound as a solid (55 mg, 24 %).
  • Step 1 A mixture of hydantoin 7 (9.2 g, 21.3 mmol, 1 equiv.), K 2 CO 3 (8.8g, 63.9 mmol, 3.0 equiv.) and tetrabutylammonium iodide (0.79 g, 2.13 mmol, 0.1 equiv.) in 180 mL acetone was stirred at room temperature for 30 minutes, treated with p-methoxybenzyl chloride (3.25 mL, 23.9 mmol, 1.12 equiv.) at reflux for 2 hours, then cooled to room temperature and filtered through sintered glass funnel.
  • DMAP 4-(dimethylamino)pyridine
  • Step 4 A solution of methyl-hydroxy-BOC-pmb-urea 122 (310 mg, 0.46 mmol, 1 equiv.) in 5 mL of dry CH 2 Cl 2 was treated with 1.16 mL of 4.0 M HCl in 1,4-dioxane at 0 C. The reaction was allowed to warm up to room temperature and stirred overnight. The crude product was taken up with Et 2 O, then washed with 3 mL of saturated NaHCO 3 . The aqueous layer was further extracted with ether.
  • Step 6 A solution of 124 (312 mg, .93 mmol, 1 equiv.) in 8 mL EtOH was reacted with NaBH 4 (600 mg, 15.9 mmol, 17 equiv.) at room temperature for 2 days.
  • the crude was partitioned between 2 X 100 mL of CH 2 Cl 2 and 100 mL saturated aq. NaHCO 3 , then washed with 80 mL of Brine.
  • the combined organic layer was dried over anhy. Na 2 SO 4 , filtered, concentrated to give 300 mg of liquid as crude.
  • Example 92 A solution of Example 92 (224 mg, 0.536 mmol, 1 equiv.) in THF (12 mL) at 0°C was treated with 2.5 M n-BuLi (215 ⁇ L, 0.536 mmol, 1 equiv.). The resulting mixture was stirred cold for 5 min. Tetrabutyl pyrophosphate (405 mg. 0.751 mmol, 1.4 equiv.) was added to the reaction mixture as a solid in one portion. The cooling bath was removed and the reaction was stirred at room temperature for 45 minutes at which point a white suspension formed. The reaction was quenched with sat. aq. NaHCO 3 (20 mL) and extracted with EtOAc (2 x 30 mL). The solution was dried (Na 2 SO 4 ), filtered, and concentrated to give crude product (461 mg). This was not purified and used crude in the next step.
  • the precipitate was filtered, washed with i PrOH (15 mL) and EtOAc (15 mL), and dried. The solid was partitioned between EtOAc (30 mL) and H 2 O (30 mL) and an emulsion formed. The emulsion was transferred in 10-12 mL portions to centrifuge tubes and centrifuged at 3000 rpm for 15 min. Decanted away the organic layer. The aqueous layers were combined, filtered, and lyophilized to provide example 165 (306 mg, 64% yield, 1:1 mixture of regioisomers 165a and 165b).
  • the in vitro and in vivo activity of the compounds of formula I can be determined by various procedures known in the art, such as a test for their ability to inhibit the activity of the NK 1 agonist Substance P.
  • % Inhibition of neurokinin agonist activity is the difference between the percent of maximum specific binding (MSB) and 100%.
  • the concentration at which the compound produces 50% inhibition of binding is then used to determine the inhibition constant (ki) using the Chang-Prusoff equation.
  • In vivo activity is measured by inhibition of agonist-induced foot tapping in the gerbil, as descibed in Science, (1998), 281 , p. 1640-1695.
  • NK 1 antagonist activity exhibits NK 1 antagonist activity to varying degrees, e.g., certain compounds have strong NK 1 antagonist activity, while others are weaker NK 1 antagonists.
  • Ki values range from about 0.1 to 1000 nM, with Ki values of about 0.1 to 100 being preferred and Ki values of 0.1 to 25 nM being more preferred. Most preferred are compounds having a Ki ⁇ 10nM for the NK 1 receptor.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • the powders and tablets may be comprised of from about 5 to about 95 percent active ingredient.
  • Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, PA.
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
  • a pharmaceutically acceptable carrier such as an inert compressed gas, e.g. nitrogen.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
  • liquid forms include solutions, suspensions and emulsions.
  • the compounds of the invention may also be deliverable transdermally.
  • the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the compound is administered orally.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the quantity of NK 1 receptor antagonists in combination with selective serotonin reuptake inhibitors in a unit dose of preparation may be varied or adjusted from about 10 mg to about 300 mg of NK 1 receptor antagonists with about 10 mg to about 100 mg of SSRI.
  • a further quantity of NK 1 receptor antagonists in combination with selective serotonin reuptake inhibitors in a unit dose of preparation may be varied or adjusted from about 50 mg to about 300 mg of NK 1 receptor antagonists with about 10 mg to about 100 mg of SSRI.
  • NK 1 receptor antagonists in combination with selective serotonin reuptake inhibitors in a unit dose of preparation may be varied or adjusted from about 50 mg to about 300 mg of NK 1 receptor antagonists with about 20 mg of SSRI, according to the particular application.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • a typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 300 mg/day, preferably 1 mg/day to 75 mg/day, in two to four divided doses.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)

Claims (19)

  1. Verbindung mit der Strukturformel
    Figure imgb0352
     oder ein pharmazeutisch annehmbares Salz davon, worin Ar1 und Ar2 unabhängig ausgewählt sind aus der Gruppe bestehend aus R17-Heteroaryl und
    Figure imgb0353
     x1 -O-, -S-, -SO-, -SO2-, -NR12-, -N (COR12) - oder -N (SO2R15) - ist;
    R1, R2, R3 und R7 jeweils unabhängig ausgewählt sind aus der Gruppe bestehend aus H, C1-C6-Alkyl, Hydroxy (C1-C3) - alkyl, C3-C8-Cycloalkyl, -CH2F, -CHF2 und -CF3; oder R1 und R2 zusammen mit dem Kohlenstoff, an den sie gebunden sind, einen C3-C6-Alkylenring bilden; oder, wenn X1 -O- , -S- oder -NR12- ist, R1 und R2 zusammen =O sind;
    jedes R6 unabhängig ausgewählt ist aus H, C1-C6-Alkyl, -OR13 oder -SR12;
    n 1 bis 4 ist, wenn n größer als 1 ist, können R6 und R7 an jedem Kohlenstoff gleich oder verschieden sein;
    Figure imgb0354
     ausgewählt ist aus der Gruppe bestehend aus
    Figure imgb0355
    X2 -O-, -S- oder -NR5- ist;
    Y =O, =S oder =NR11 ist;
    Y1 H, C1-C6-Alkyl , -NR17R13, -SCH3, R19-Aryl (CH2) n6-, R19-Heteroaryl- (CH2) n6-, - (CH2) n6-Heterocycloalkyl, - (C1-C3) - Alkyl-NH-C (O) O (C1-C6) alkyl oder -NHC(O)R15 ist;
    R5 H oder - (CH2)n1-G ist, wobei n1 0 bis 5 ist, G H, -CF3, -CHF2, -CH2F, -OH, -O- (C1-C6-Alkyl), -SO2R13, -O- (C3-C8-Cycloalkyl) , -NR13R14, -SO2N13R14-, -NR13SO2R15, -NR13COR12, -NR12 (CONR13R14), -CONR13R14, -COOR12, C3-C8-Cycloalkyl, R19-Aryl, R19-Heteroaryl,
    Figure imgb0356
    Figure imgb0357
     ist;
    oder wenn n1 0 ist, R5 auch -C (O) R13 oder -C (S) R13 sein kann, mit der Maßgabe, dass G nicht H ist, wenn n1 = 0 ist;
    X -NR20-, -N (CONR13R14) -, -N (CO2R13) -, -N (SO2R15) -, -N (COR12) -, N (SO2NHR13)-, -O-, -S-, -SO-, -SO2-, -CF2-, -CH2- oder -CR12F- ist;
    R8, R9 und R10 unabhängig ausgewählt sind aus der Gruppe bestehend aus H, C1-C6-Alkyl, C3-C8-Cycloalkyl, -OR12, Halogen, -CN, -NO2, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -COOR12, -CONR21R22, -NR21COR12, -NR21CO2R15, -NR21CONR21R22, -NR21SO2R15, -NR21R22, -SO2NR21R22, -S (O) n5R15, R16-aryl und R19-Heteroaryl;
    R11 H, C1-C6-Alkyl, C3-C8-Cycloalkyl, -NO2, -CN, OH, -OR12, - O (CH2) n6R12, -(C1-C3) -Alkyl-C (O) NHR12, R19-Aryl (CH2) n6- oder R19-Heteroaryl- (CH2) n6- ist;
    R4 und R12 jeweils unabhängig ausgewählt sind aus der Gruppe bestehend aus H, C1-C6-Alkyl und C3-C8-Cycloalkyl;
    R13 und R14 unabhängig ausgewählt sind aus der Gruppe bestehend aus H, C1-C6-Alkyl, C3-C8-Cycloalkyl, R19-Aryl-(CH2)n6- oder R19-Heteroaryl-(CH2)n6-; oder R13 und R14 zusammen C3-C8-Alkylen sind und mit dem Stickstoff, an den sie gebunden sind, einen 4-7-gliedrigen Ring bilden, oder eines der Kohlenstoffatome in der durch R13 und R14 gebildeten Alkylengruppe durch ein Heteroatom ausgewählt aus der Gruppe bestehend aus -O-, -S- und -NR12- ersetzt wird;
    R15 C1-C6-Alkyl, C3-C9-Cycloalkyl oder -CF3 ist;
    R16 1 bis 3 Substituenten ist, die unabhängig ausgewählt sind aus der Gruppe bestehend aus H, C1-C6-Alkyl, C3-C8-Cycloalkyl, C1-C6-Alkoxy, Halogen und -CF3;
    R17 H, C1-C6-Alkyl, C3-C9-Cycloalkyl, -COOR12, CONR21R22, -NR21R22, -NR21COR12, -NR21CO2R12, -NR21CONR21R22, -NR21SO2R15 oder -S(O)n5R15 ist;
    R18 H, C1-C6-Alkyl oder -P(O) (OH)2 ist;
    R19 1 bis 3 Substituenten ist, die unabhängig ausgewählt sind aus der Gruppe bestehend aus H, C1-C6-Alkyl, C3-C8-Cycloalkyl, -OH, Halogen, -CN, -NO2, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -O-(C1-C6-Alkyl), -O- (C3-C8-Cycloalkyl), -COOR12, -CONR21R22, -NR21R22, -NR21COR12, -NR21CO2R12, -NR21CONR21R22, -NR21SO2R15 und -S (O) n5R15;
    R20 H, C1-C6-Alkyl, C3-C8-Cycloalkyl oder - (CH2) n6-Heterocycloalkyl ist;
    R21 und R22 unabhängig ausgewählt sind aus der Gruppe bestehend aus H, C1-C6-Alkyl, C3-C8-Cycloalkyl und Benzyl; oder R21 und R22 zusammen C3-C6-Alkylen sind und mit dem Stickstoff, an den sie gebunden sind, einen 4-7-gliedrigen Ring bilden, oder eines der Kohlenstoffatome in der durch R21 und R22 gebildeten Alkylengruppe durch ein Heteroatom ausgewählt aus der Gruppe bestehend aus -O-, -S- und -NR12- ersetzt ist;
    R23, R24, R25 und R26 H, C1-C6-Alkyl sind und zusammen als =O vorliegen können; wenn n5 = 0, und R25 und R26 = H, ist X nicht O, N, S;
    n3 und n4 unabhängig 1 bis 5 sind, mit der Maßgabe, dass die Summe von n3 und n4 2 bis 6 ist;
    n5 unabhängig 0 bis 2 ist; und
    n6 unabhängig 0 bis 3 ist,
    worin:
    "Aryl" Phenyl, Naphthyl, Indenyl, Tetrahydronaphthyl, Indanyl, Anthracenyl oder Fluorenyl bedeutet,
    "Heteroaryl" 5- bis 10-gliedrige einzelne oder benzokondensierte aromatische Ringe bedeutet, die 1 bis 4 Heteroatome aufweisen, die unabhängig aus der Gruppe bestehend aus -O-, -S-, -N= und -NH- ausgewählt sind, mit der Maßgabe, dass die Ringe keine benachbarten Sauerstoff-und/oder Schwefelatome einschließen, und
    "Heterocycloalkyl" 4- bis 7-gliedrige gesättigte Ringe bedeutet, die 1 bis 3 Heteroatome aufweisen, die unabhängig ausgewählt sind aus der Gruppe bestehend aus -O-, -S-und -NR21-, worin R21 H oder C1-C6-Alkyl ist, und wobei die restlichen Ringglieder Kohlenstoff sind.
  2. Verbindung nach Anspruch 1, bei der R1, R3, R4 und R7 jeweils Wasserstoff sind.
  3. Verbindung nach Anspruch 1, bei der R6 H oder OH ist.
  4. Verbindung nach Anspruch 1, bei der X1 -O- oder -NR12- ist.
  5. Verbindung nach Anspruch 1, bei der Ar1 und Ar2 jeweils R8, R9, R10-Phenyl sind.
  6. Verbindung nach Anspruch 1, bei der
    Figure imgb0358
    Figure imgb0359
     ist.
  7. Verbindung nach Anspruch 6, bei der n 1 oder 2 ist.
  8. Verbindung nach Anspruch 7, bei der X2 -NR5- ist und Y =O ist.
  9. Verbindung nach Anspruch 1, bei der R1, R3, R4 und R7 jeweils Wasserstoff sind; X1 -O- oder -NR12- ist; Ar1 und Ar2 jeweils R8,R9,R10-Phenyl sind; n 1 oder 2 ist; X2 -NR5- ist; und R6 H oder -OH ist, Y =O ist.
  10. Verbindung nach Anspruch 1 ausgewählt aus der Gruppe von Verbindungen, die durch die Formel
    Figure imgb0360
    Figure imgb0361
     wiedergegeben werden, worin R8 H oder Halogen ist; R2 H, -CH3 oder -CH2OH ist; R6 H oder -OH ist; und R5 ausgewählt ist aus der Gruppe bestehend aus Wasserstoff und Gruppen mit der Formel (CH2)n1-G.
  11. Verbindung nach Anspruch 10, bei der X1 -O-, -NH-, -N(CH3) - oder -N(COCH3) ist; R8 H oder Halogen ist; R2 H, -CH3 oder -CH2OH ist; R6 H oder -OH ist; R9 -OCF3 oder 5-(Trifluoromethyl)-1H-tetrazol-1-yl ist; R12 -CH3 oder Cyclopropyl ist, und R5 ausgewählt ist aus der Gruppe bestehend aus Wasserstoff und Gruppen mit der Formel - (CH2)n1-G, wobei - (CH2) n1-G ausgewählt ist aus der Gruppe bestehend aus
    Figure imgb0362
    Figure imgb0363
     oder - (CH2)n1-G', wobei n1 2 bis 4 ist und G' H, -OH, -OCH3, Ethoxy, Isopropyloxy, -O-Cyclopropyl oder -CONR13R14 ist, wobei R13 und R14 unabhängig ausgewählt sind aus der Gruppe bestehend aus H, -CH3, Ethyl, Isopropyl oder Cyclopropyl.
  12. Verbindung nach Anspruch 1 ausgewählt aus den folgenden Strukturen:
    Figure imgb0364
    Figure imgb0365
    Figure imgb0366
    Figure imgb0367
    Figure imgb0368
    Figure imgb0369
    Figure imgb0370
    Figure imgb0371
    Figure imgb0372
    Figure imgb0373
    Figure imgb0374
    Figure imgb0375
    Figure imgb0376
    Figure imgb0377
    Figure imgb0378
    Figure imgb0379
    Figure imgb0380
    Figure imgb0381
    Figure imgb0382
    Figure imgb0383
    Figure imgb0384
    Figure imgb0385
    Figure imgb0386
    Figure imgb0387
    Figure imgb0388
    Figure imgb0389
    Figure imgb0390
    Figure imgb0391
    Figure imgb0392
    Figure imgb0393
    Figure imgb0394
    Figure imgb0395
    Figure imgb0396
    Figure imgb0397
    Figure imgb0398
    Figure imgb0399
    Figure imgb0400
    Figure imgb0401
    Figure imgb0402
    Figure imgb0403
    Figure imgb0404
    Figure imgb0405
    Figure imgb0406
    Figure imgb0407
    Figure imgb0408
    Figure imgb0409
    Figure imgb0410
    Figure imgb0411
    Figure imgb0412
    Figure imgb0413
    Figure imgb0414
    Figure imgb0415
    Figure imgb0416
    Figure imgb0417
    Figure imgb0418
    Figure imgb0419
    Figure imgb0420
    Figure imgb0421
    Figure imgb0422
    Figure imgb0423
    Figure imgb0424
    Figure imgb0425
    Figure imgb0426
    Figure imgb0427
    Figure imgb0428
    Figure imgb0429
    Figure imgb0430
    Figure imgb0431
    Figure imgb0432
    Figure imgb0433
    Figure imgb0434
    Figure imgb0435
  13. Verbindung nach Anspruch 12 ausgewählt aus den Verbindungen Nr. 2, 17, 19, 31, 59, 61, 65, 67, 76, 77, 78, 79a, 79b, 92, 93, 99, 100, 103, 104, 110, 111, 113, 120, 121, 126, 127, 128, 129, 130, 135, 142, 165, 165a, 165b, 166a, 166b oder Verbindung 118.
  14. Pharmazeutische Zusammensetzung, die eine wirksame Menge einer Verbindung gemäß Anspruch 1 bis 13 und einen pharmazeutisch annehmbaren Träger enthält.
  15. Pharmazeutische Zusammensetzung, die eine wirksame Menge einer Verbindung gemäß Anspruch 1 bis 13 in Kombination einer wirksamen Menge eines selektiven Serotonin-Wiederaufnahmeinhibitors und einem pharmazeutisch annehmbaren Träger enthält.
  16. Verwendung der Verbindungen gemäß Ansprüchen 1 bis 13 zur Herstellung eines Medikaments zur Behandlung von Atemwegserkrankungen, entzündlichen Erkrankungen, Hautproblemen, ophthalmologischen Störungen, Suchterkrankungen, mit Stress zusammenhängenden Störungen, Zwangsstörungen, Essstörungen, Manie, prämenstruellem Syndrom, Zuständen des zentralen Nervensystems, gastrointestinalen Störungen, Blasenstörungen, Arteriosklerose, fibrosierenden Störungen, Fettleibigkeit, Diabetes Typ II, mit Schmerz zusammenhängenden Störungen und Urogenitalstörungen.
  17. Verwendung der Verbindungen gemäß Ansprüchen 1 bis 13 in Kombination mit einem selektiven Serotonin-Wiederaufnahmeinhibitors zur Herstellung eines Medikaments zur Behandlung von Atemwegserkrankungen, entzündlichen Erkrankungen, Hautproblemen, ophthalmologischen Störungen, Suchterkrankungen, mit Stress zusammenhängenden Störungen, Zwangsstörungen, Essstörungen, Manie, prämenstruellem Syndrom, Zuständen des zentralen Nervensystems, gastrointestinalen Störungen, Blasenstörungen, Arteriosklerose, fibrosierenden Störungen, Fettleibigkeit, Diabetes Typ II, mit Schmerz zusammenhängenden Störungen und Urogenitalstörungen.
  18. Verwendung der Verbindungen gemäß Ansprüchen 1 bis 13 zur Herstellung eines Medikaments zur Behandlung von Erbrechen, Depression, Ängstlichkeit und Husten.
  19. Verwendung der Verbindungen gemäß Ansprüchen 1 bis 13 in Kombination mit einem selektiven Serotonin-Wiederaufnahmeinhibitor zur Herstellung eines Medikaments zur Behandlung von Erbrechen, Depression, Ängstlichkeit und Husten.
EP00984340A 1999-12-17 2000-12-14 Selektive neurokinin-antagonisten Expired - Lifetime EP1237874B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17248999P 1999-12-17 1999-12-17
US172489P 1999-12-17
PCT/US2000/033831 WO2001044200A2 (en) 1999-12-17 2000-12-14 Selective neurokinin antagonists

Publications (2)

Publication Number Publication Date
EP1237874A2 EP1237874A2 (de) 2002-09-11
EP1237874B1 true EP1237874B1 (de) 2006-02-22

Family

ID=22627912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00984340A Expired - Lifetime EP1237874B1 (de) 1999-12-17 2000-12-14 Selektive neurokinin-antagonisten

Country Status (19)

Country Link
EP (1) EP1237874B1 (de)
JP (1) JP2003522739A (de)
KR (1) KR20020067548A (de)
CN (1) CN1434805A (de)
AR (1) AR026990A1 (de)
AT (1) ATE318259T1 (de)
AU (1) AU2097601A (de)
CA (1) CA2393672A1 (de)
CO (1) CO5261559A1 (de)
DE (1) DE60026169T2 (de)
EC (1) ECSP003828A (de)
ES (1) ES2258485T3 (de)
HK (1) HK1045308A1 (de)
HU (1) HUP0301607A3 (de)
IL (1) IL150033A0 (de)
MX (1) MXPA02006017A (de)
PE (1) PE20011035A1 (de)
WO (1) WO2001044200A2 (de)
ZA (1) ZA200204395B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004477A (es) * 2001-11-13 2004-08-11 Schering Corp Antagonistas del neuropeptido neuroquinina-1(nk1).
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
KR100755577B1 (ko) * 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체
EP1501808B1 (de) * 2002-04-26 2008-07-02 Eli Lilly And Company Tachykininrezeptorantagonisten
US7041682B2 (en) * 2002-07-03 2006-05-09 Schering Corporation NK1 antagonists
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
BRPI0807972A2 (pt) 2007-01-24 2014-06-10 Glaxo Group Ltd Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1
CA2678577A1 (en) 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
JP5451611B2 (ja) 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
US8440658B2 (en) 2007-12-11 2013-05-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
CA2712500A1 (en) * 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2252598A2 (de) 2008-02-11 2010-11-24 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-on und 1,3-diazepan-2-on als inhibitoren von 11beta-hydroxysteroiddehydrogenase 1
JP5730021B2 (ja) 2008-02-15 2015-06-03 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロアルキルラクタム誘導体
EP2300461B1 (de) 2008-05-01 2013-04-17 Vitae Pharmaceuticals, Inc. Cyclische inhibitoren von 11beta-hydroxysteroiddehydrogenase 1
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
EP2291371B1 (de) 2008-05-01 2015-06-10 Vitae Pharmaceuticals, Inc. Cyclische inhibitoren von 11beta-hydroxysteroiddehydrogenase 1
JP5451752B2 (ja) 2008-05-01 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
CA2729993A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
WO2010010157A2 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
EP2687525B1 (de) 2008-07-25 2015-09-23 Boehringer Ingelheim International GmbH Cyclische inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
AU2009289598B2 (en) 2008-09-05 2014-09-11 Opko Health, Inc. Process and intermediates for the synthesis of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
JP5679997B2 (ja) 2009-02-04 2015-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
ES2609640T3 (es) 2009-08-14 2017-04-21 Opko Health, Inc Formulaciones intravenosas de rolapitant
US8552212B2 (en) 2009-11-05 2013-10-08 Boehringer Ingelheim International Gmbh Chiral phosphorus ligands
WO2011149822A1 (en) 2010-05-26 2011-12-01 Boehringer Ingelheim International Gmbh 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
EP2585444B1 (de) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanone als 11-beta-hsd1-hemmer zur behandlung von stoffwechselerkrankungen
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US20180360040A1 (en) * 2015-12-03 2018-12-20 Syngenta Participations Ag Pesticidal compounds and their uses
EP3822268A1 (de) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituierte hydantoinamide als adamts7 antagonisten
EP3822265A1 (de) 2019-11-15 2021-05-19 Bayer AG Substituierte hydantoinamide als adamts7 antagonisten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620989A (en) * 1992-10-28 1997-04-15 Merck Sharp & Dohme Limited 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits
GB9601680D0 (en) * 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
HUP0301607A2 (hu) 2003-12-29
ES2258485T3 (es) 2006-09-01
JP2003522739A (ja) 2003-07-29
ATE318259T1 (de) 2006-03-15
EP1237874A2 (de) 2002-09-11
ECSP003828A (es) 2002-02-25
WO2001044200A2 (en) 2001-06-21
CA2393672A1 (en) 2001-06-21
CO5261559A1 (es) 2003-03-31
AR026990A1 (es) 2003-03-05
WO2001044200A3 (en) 2001-12-13
PE20011035A1 (es) 2001-10-13
HUP0301607A3 (en) 2004-03-29
ZA200204395B (en) 2003-11-26
CN1434805A (zh) 2003-08-06
KR20020067548A (ko) 2002-08-22
AU2097601A (en) 2001-06-25
HK1045308A1 (zh) 2002-11-22
DE60026169D1 (de) 2006-04-27
DE60026169T2 (de) 2006-11-09
IL150033A0 (en) 2002-12-01
MXPA02006017A (es) 2002-12-05

Similar Documents

Publication Publication Date Title
EP1237874B1 (de) Selektive neurokinin-antagonisten
US6635630B2 (en) Selective neurokinin antagonists
EP3538526B1 (de) Cyclobutan- und azetidinhaltige mono- und spirocyclische verbindungen als alpha-v-integrin-inhibitoren
RU2726631C1 (ru) Гетероциклические спиросоединения в качестве ингибиторов magl
KR100660309B1 (ko) 시아노페닐 유도체
DE60112791T2 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität
EP3634958B1 (de) Cyclopropyl-harnstoff-formylpeptid-2-rezeptor- und formylpeptid-1-rezeptor-agonisten
EP1461040B1 (de) Succinate des 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
PL185029B1 (pl) Nowa 1-(1,2-dwupodstawiona-piperydynylo)-4-podstawiona pochodna piperazyny, kompozycja farmaceutyczna, sposób wytwarzania kompozycji farmaceutycznej i sposób wytwarzania 1-(1,2-dwupodstawionej-piperydynylo)-4-podstawionej pochodnej piperazyny
KR102504830B1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물
US20120041026A1 (en) (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
EP1646620B1 (de) Substituierte piperidine als histamin-h3-rezeptorliganden
KR20070064437A (ko) 환상 아민 유도체 또는 그의 염
AU2021396593A1 (en) Novel compounds as androgen receptor and phosphodiesterase dual inhibitor
ZA200402191B (en) Muscarinic agonists.
AU2019242518A1 (en) Compound with anticancer activity
CN108148060B (zh) 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途
CA2995161A1 (en) 2,3,4,5-tetrahydropyridin-6-amine derivatives
JP2002532471A (ja) ５−ｈｔ１ａ受容体活性を有するアリールピペリジンおよびアリール−１，２，５，６−テトラヒドロピリジンアミド誘導体
US et al. SELECTIVE NEUROKININ ANTAGONISTS
CN111655682B (zh) 一种高活性sting蛋白激动剂化合物
WO2022249006A1 (en) Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
AU2022281345A1 (en) Substituted fused bicyclic macrocyclic compounds and related methods of treatment
AU2022267220A1 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
JPH09291090A (ja) ピペリジノンおよびホモピペリジノン誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020618

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO PAYMENT 20020618;SI PAYMENT 20020618

17Q First examination report despatched

Effective date: 20040310

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: RO SI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060222

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060222

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060222

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060222

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060222

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060222

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60026169

Country of ref document: DE

Date of ref document: 20060427

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060522

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060724

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2258485

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061214

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

26N No opposition filed

Effective date: 20061123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060523

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1045308

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060222

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20091217

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20091221

Year of fee payment: 10

Ref country code: GB

Payment date: 20091106

Year of fee payment: 10

Ref country code: FR

Payment date: 20091215

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20091230

Year of fee payment: 10

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20101214

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110103

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60026169

Country of ref document: DE

Effective date: 20110701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110701

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101214

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20120206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101215